Gene signature can predict who will survive chemotherapy

April 15, 2013

An eight gene 'signature' can predict length of relapse-free survival after chemotherapy, finds new research in Biomed Central's open access journal BMC Medicine.

Researchers from Academia Sinica and the National Taiwan University College of Medicine first identified genes that were involved in cellular invasion, a property of many cancer cells, using the 's 60 human cancer cell line panel (NCI-60). Comparing the pattern of activation of each of these genes in different cell lines with how these cell lines responded to 99 different anti-, helped narrow down the list of genes to just those which could potentially influence the outcome of chemotherapy.

Testing this link, Prof Ker-Chau Li, from Academia Sinica and UCLA, commented, "Our study found eight genes which were involved in invasion, and the relative activation of these genes correlated to chemotherapy outcome, including the receptor for growth factor EGF. We also found that some invasion genes had unique patterns of expression that reflect the differential cell responses to each of the - five drugs (paclitaxel, docetaxel, erlotinib, everolimus and dasatinib) had the greatest effect."

When the researchers looked at of these eight genes from cancer cell lines they found that there was an obvious difference between cells which responded to chemotherapy and those who did not (albeit with some overlap). In clinical studies, looking at lung and breast cancer, the patients, whose gene signature put them in the low-risk group, had a longer relapse free survival than the high-risk group.

Prof Pan-Chyr Yang of National Taiwan University added, "The discovery of prognostic biomarkers for remains critical toward improving the efficacy of cancer treatment. The eight-gene signature obtained here may help choice of treatment as part of individualized cancer therapy and our method of gene discovery may be applicable in studying other cancers."

Explore further: Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer

More information: Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity, Yi-Chiung Hsu, Hsuan-Yu Chen, Shinsheng Yuan, Sung-Liang Yu, Chia-Hung Lin, Guani Wu, Pan-Chyr Yang and Ker-Chau Li, BMC Medicine 2013 , 11:106. doi:10.1186/1741-7015-11-106

Related Stories

Genetic predictor of breast cancer response to chemotherapy

May 10, 2012

Chemotherapy is a major first line defense against breast cancer. However a patient's response is often variable and unpredictable. A study published in BioMed Central's open access journal BMC Medical Genomics shows that ...

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.